» Articles » PMID: 25298741

Metabolic Consequences of Second-generation Antipsychotics in Youth: Appropriate Monitoring and Clinical Management

Overview
Publisher Dove Medical Press
Date 2014 Oct 10
PMID 25298741
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To review the metabolic consequences of second-generation antipsychotics in youth and current monitoring and intervention guidelines for optimal treatment.

Background: Second-generation antipsychotics have largely replaced the use of first-generation antipsychotics in treating psychotic disorders in youth. In addition, there has been a dramatic increase in using these medications to treat a variety of nonpsychotic disorders. These medications have significant metabolic side effects, including weight gain. This raises concern, given the problem of pediatric obesity.

Materials And Methods: A review of current literature looking at prescribing practices and possible reasons for the increased use of second-generation antipsychotics in children and adolescents was conducted. Review of the mechanisms for why youth may be particularly vulnerable to the metabolic consequences (particularly weight gain) was similarly completed. In addition, data supporting the efficacy, rationale, and unique side-effect profile of each individual second-generation drug were evaluated to help inform providers on when and what to prescribe, along with current monitoring practices. The current evidence base for possible interventions regarding the management of antipsychotic-induced weight gain was also evaluated.

Results And Conclusion: On the basis of the literature review, there are several speculated reasons for the increase in prescriptions of second-generation antipsychotics. The choice of antipsychotic for youth should be based upon the disorder being treated along with the unique side-effect profile for the most commonly used second-generation antipsychotics. Monitoring strategies are also individualized to each antipsychotic. The current interventions recommended for antipsychotic-induced weight gain include lifestyle management, switching medication to a drug with a lower propensity for weight gain, and pharmacologic (particularly metformin) treatment.

Citing Articles

Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.

Chisamore N, Danayan K, Rodrigues N, Di Vincenzo J, Meshkat S, Doyle Z J Psychopharmacol. 2023; 37(8):775-783.

PMID: 37194253 PMC: 10399094. DOI: 10.1177/02698811231171531.


Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review.

DAlo G, De Crescenzo F, Amato L, Cruciani F, Davoli M, Fulceri F BMC Psychiatry. 2020; 20(1):561.

PMID: 33238921 PMC: 7687819. DOI: 10.1186/s12888-020-02956-8.


Metabolic monitoring in children 5 years of age and younger prescribed second-generation antipsychotic medications.

Kauffman Y, Delate T, Botts S Ment Health Clin. 2018; 7(1):1-6.

PMID: 29955489 PMC: 6007660. DOI: 10.9740/mhc.2017.01.001.


Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.

Medici V, McClave S, Miller K Curr Gastroenterol Rep. 2015; 18(1):2.

PMID: 26700070 DOI: 10.1007/s11894-015-0479-4.

References
1.
Sikich L, Frazier J, McClellan J, Findling R, Vitiello B, Ritz L . Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008; 165(11):1420-31. DOI: 10.1176/appi.ajp.2008.08050756. View

2.
Seida J, Schouten J, Boylan K, Newton A, Mousavi S, Beaith A . Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics. 2012; 129(3):e771-84. DOI: 10.1542/peds.2011-2158. View

3.
DelBello M, Kowatch R, Adler C, Stanford K, Welge J, Barzman D . A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006; 45(3):305-313. DOI: 10.1097/01.chi.0000194567.63289.97. View

4.
Correll C, Sikich L, Reeves G, Riddle M . Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?. Am J Psychiatry. 2013; 170(9):947-52. DOI: 10.1176/appi.ajp.2013.13060771. View

5.
Pringsheim T, Panagiotopoulos C, Davidson J, Ho J . Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health. 2012; 16(9):581-9. PMC: 3223902. View